Cogent Biosciences, Inc. Common Stock (COGT) is a publicly traded Healthcare sector company. As of May 20, 2026, COGT trades at $33.05 with a market cap of $5.36B and a P/E ratio of -15.19. COGT moved +5.44% today. Year to date, COGT is -3.90%; over the trailing twelve months it is +520.06%. Its 52-week range spans $3.72 to $43.73. Analyst consensus is strong buy with an average price target of $52.10. Rallies surfaces COGT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Cogent Biosciences slips as investors digest Q1 loss and long PDUFA timeline: Cogent Biosciences shares fell about 3% on May 6, 2026 to $35.77 as investors digested its newly filed Q1 2026 results and near-term catalyst calendar. The company reported a wider Q1 net loss of $97.4 million (EPS -$0.53) and reiterated regulatory timelines, including a Dec. 30, 2026 PDUFA date for bezuclastinib in NonAdvSM.
| Metric | Value |
|---|---|
| Price | $33.05 |
| Market Cap | $5.36B |
| P/E Ratio | -15.19 |
| EPS | $-2.16 |
| Dividend Yield | 0.00% |
| 52-Week High | $43.73 |
| 52-Week Low | $3.72 |
| Volume | 1.54M |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-328.94M |
| Gross Margin | 0.00% |
11 analysts cover COGT: 0 strong buy, 9 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $52.10.